Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
8Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Foghorn Therapeutics Inc. (FHTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
3Distinct source URLs
7High confidence
0.776Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Concurrent with the Lilly Collaboration Agreement, we also entered into a stock purchase agreement (the "Lilly SPA") with Lilly whereby we issued and sold Lilly 4,000,000 shares of our common stock, …
Reciprocal relationship from LLY graph: Reciprocal relationship from FHTX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from FHTX graph: Reciprocal relationship from LLY grap…
Foghorn Therapeutics Inc. Customers
Ticker
Name
Confidence
Evidence
LILLY
LILLY
92%
Lilly is a leading oncology company with a track record of innovation and execution
Reciprocal relationship from LLY graph: Reciprocal relationship from FHTX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from FHTX graph: Reciprocal relationship from LLY grap…
e than 500,000 cancer patients. We take a small molecule modality agnostic approach to drugging 63 Table of Contents targets which includes protein degraders, allosteric enzymatic inhibitors, and tra…
DEERFIELD-MANAGEMENT-CO
DEERFIELD-MANAGEMENT-CO
62%
subcommittees represent a single performance obligation under the Lilly Collaboration Agreement. The Company determined that Lilly cannot benefit from the licenses separately from the research activi…
EVERCORE-GROUP-LLC
EVERCORE-GROUP-LLC
62%
e than 500,000 cancer patients. We take a small molecule modality agnostic approach to drugging 63 Table of Contents targets which includes protein degraders, allosteric enzymatic inhibitors, and tra…
Reciprocal relationship from EVR graph: Reciprocal relationship from FHTX graph: Reciprocal relationship from EVR graph: Reciprocal relationship from FHTX graph: e than 500,000 cancer patients. We ta…
FLAGSHIP-PIONEERING-INC
FLAGSHIP-PIONEERING-INC
62%
subcommittees represent a single performance obligation under the Lilly Collaboration Agreement. The Company determined that Lilly cannot benefit from the licenses separately from the research activi…
FMR-LLC
FMR-LLC
62%
subcommittees represent a single performance obligation under the Lilly Collaboration Agreement. The Company determined that Lilly cannot benefit from the licenses separately from the research activi…
Foghorn Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
FHTX-DEBT-9496
Warrants outstanding: 114000
90%
xbrl warrant detail from xbrl 2021-12-31.
FHTX-DEBT-9497
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
FHTX-DEBT
Debt stack $42.0M
90%
Market cache reports total debt of $42.0M.
Foghorn Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Foghorn Therapeutics Inc..
Foghorn Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
FHTX-OWNER-FLAGSHIP-PIONEERING-LLC
Flagship Pioneering, LLC
90%
13F overlay lists Flagship Pioneering, LLC as top holder; 105 tracked holders.
Foghorn Therapeutics Inc. Extended Supply Chain Network
